Alembic Pharmaceuticals Limited (BOM: 533573)

Alembic Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	1,290	1,202	754.8	610.9	980.6	718.4
Trading Asset Securities	-	-	-	-	1,870	-
Cash & Short-Term Investments	1,290	1,202	754.8	610.9	2,850	718.4
Cash Growth	-12.75%	59.26%	23.56%	-78.57%	296.76%	-63.91%
Accounts Receivable	12,677	10,248	10,464	8,071	3,486	8,648
Other Receivables	278.1	477.5	827.1	250.8	166	309.8
Receivables	12,955	10,726	11,291	8,322	3,652	8,957
Inventory	20,125	16,435	14,753	16,097	14,862	11,875
Prepaid Expenses	-	500.5	553.2	370.7	357.3	281
Other Current Assets	3,254	1,922	1,748	3,207	4,799	2,796
Total Current Assets	37,624	30,786	29,100	28,608	26,520	24,628
Property, Plant & Equipment	31,249	30,711	29,997	39,473	36,472	30,990
Long-Term Investments	1,018	930.2	963.3	1,184	493.1	176.2
Other Intangible Assets	-	-	-	1,548	3,238	2,990
Long-Term Deferred Tax Assets	1,993	1,696	1,230	58.8	-	-
Other Long-Term Assets	419.2	332.9	537.4	348.8	367.2	1,107
Total Assets	72,303	64,456	61,828	71,220	67,090	59,891
Accounts Payable	8,892	7,356	6,798	7,064	6,688	6,259
Accrued Expenses	-	1,582	1,418	1,850	1,832	1,266
Short-Term Debt	-	4,305	6,359	4,300	0.2	8,605
Current Portion of Long-Term Debt	9,950	-	-	2,000	2,999	-
Current Portion of Leases	179.7	198.3	169.2	149.8	122.8	99
Current Income Taxes Payable	-	-	-	-	21.5	-
Current Unearned Revenue	-	114.5	112.7	123.6	118.6	119.8
Other Current Liabilities	2,697	994.3	1,512	1,678	1,027	1,167
Total Current Liabilities	21,718	14,550	16,369	17,165	12,808	17,516
Long-Term Debt	-	-	-	-	1,999	8,870
Long-Term Leases	534.3	628.8	692.3	721.4	715.4	733
Long-Term Deferred Tax Liabilities	-	-	-	-	42.1	121.9
Other Long-Term Liabilities	1,174	1,005	1,005	958.1	855.3	737.5
Total Liabilities	23,426	16,274	18,124	18,845	16,420	27,986
Common Stock	393.1	393.1	393.1	393.1	393.1	377
Additional Paid-In Capital	-	7,484	7,484	7,484	7,484	-
Retained Earnings	-	40,273	35,687	43,991	41,550	30,750
Comprehensive Income & Other	48,488	32.4	140.8	507.2	1,243	1,068
Total Common Equity	48,881	48,182	43,705	52,376	50,670	32,194
Minority Interest	-4.2	-	-	-	-	-289.6
Shareholders' Equity	48,876	48,182	43,705	52,376	50,670	31,905
Total Liabilities & Equity	72,303	64,456	61,828	71,220	67,090	59,891
Total Debt	10,664	5,132	7,220	7,171	5,836	18,307
Net Cash (Debt)	-9,374	-3,930	-6,465	-6,560	-2,986	-17,589
Net Cash Per Share	-47.67	-19.99	-32.89	-33.37	-15.41	-93.30
Filing Date Shares Outstanding	196.93	196.56	196.56	196.56	196.56	188.52
Total Common Shares Outstanding	196.93	196.56	196.56	196.56	196.56	188.52
Working Capital	15,906	16,236	12,731	11,443	13,712	7,112
Book Value Per Share	248.21	245.12	222.34	266.46	257.78	170.78
Tangible Book Value	48,881	48,182	43,705	50,827	47,432	29,204
Tangible Book Value Per Share	248.21	245.12	222.34	258.58	241.31	154.91
Land	-	1,013	1,017	931.4	1,138	1,112
Buildings	-	7,465	7,068	5,277	5,084	4,487
Machinery	-	28,487	24,961	18,291	16,399	13,677
Construction In Progress	-	5,244	6,013	22,058	19,443	15,741
Leasehold Improvements	-	18.3	7.9	7.3	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.